Apurano Pharmaceuticals GmbH
🇩🇪Germany
Clinical Trials
8
Active:0
Completed:0
Trial Phases
1 Phases
Phase 3:8
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 3
8 (100.0%)Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
Phase 3
Recruiting
- Conditions
- Neuropathic PainPeripheral NeuropathyPainPain SyndromePain, ChronicChronic PainPost-Traumatic NeuralgiaChronic Pain SyndromePeripheral Nerve InjuryPost Operative Pain
- Interventions
- Drug: Adezunap (AP707)Drug: Placebo
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Apurano Pharmaceuticals GmbH
- Target Recruit Count
- 558
- Registration Number
- NCT06071936
- Locations
- 🇩🇪
Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie), Munich, Bavaria, Germany
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
Phase 3
Recruiting
- Conditions
- Peripheral NeuralgiaPeripheral NeuropathyPainPain SyndromePain, ChronicDiabetesPeripheral Neuropathy With Type 2 DiabetisChronic PainChronic Pain SyndromeDiabetic Neuropathies
- Interventions
- Drug: Adezunap (AP707)Drug: Placebo
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Apurano Pharmaceuticals GmbH
- Target Recruit Count
- 558
- Registration Number
- NCT06072573
- Locations
- 🇩🇪
Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie), Munich, Bavaria, Germany
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain
Phase 3
Recruiting
- Conditions
- Pain SyndromeChronic PainPainPain, ChronicLower Back PainChronic Pain SyndromeBack PainLower Back Pain Chronic
- Interventions
- Drug: PlaceboDrug: Adezunap (AP707)
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Apurano Pharmaceuticals GmbH
- Target Recruit Count
- 558
- Registration Number
- NCT06071962
- Locations
- 🇩🇪
Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie), Munich, Bavaria, Germany
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Phase 3
Recruiting
- Conditions
- Pain SyndromeCentral Neuropathic PainPhantom Limb Syndrome With PainPainChronic Pain SyndromePhantom PainTraumatic Brain InjuryPain, ChronicChronic PainNeuropathic Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Apurano Pharmaceuticals GmbH
- Target Recruit Count
- 558
- Registration Number
- NCT06071949
- Locations
- 🇩🇪
Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie), Munich, Bavaria, Germany
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
Phase 3
Recruiting
- Conditions
- Pain SyndromePeripheral NeuropathyChronic PainChronic Pain SyndromeDiabetic NeuropathiesPeripheral NeuralgiaDiabetesDiabetic PolyneuropathyPeripheral Neuropathy With Type 2 DiabetisPain
- Interventions
- Drug: Adezunap (AP707)Drug: Placebo
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Apurano Pharmaceuticals GmbH
- Target Recruit Count
- 558
- Registration Number
- NCT06071975
- Locations
- 🇩🇪
Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie), Munich, Bavaria, Germany
- Prev
- 1
- 2
- Next
News
No news found